Drug Discovery Technology Alert. Glutaminyl Cyclase Inhibitors Being Developed for Treating Alzheimer's Disease; Bispecific Antibody for Treatment of Acute Lymphoblastic Leukemia; Chromatin Regulating Protein Complex as a Potential Target for AML
This issue profiles glutaminyl cyclase inhibitors being developed for treating Alzheimers Disease, bispecific antibodies for treatment of acute lymphoblastic leukemia, and using chromatin regulating protein complex as a potential target for AML.
Click headings to expand and collapse
Published: 13 Apr 2012
Tools
Features of this research
Help Desk
For more information and general enquiries, contact Frost & Sullivan near you.
Select a location near you..